Susquehanna Portfolio Strategies’s Fulcrum Therapeutics FULC Stock Holding History
Bought
Maintained
Sold
Other funds holding FULC
EC
TCM
SCM
Susquehanna Portfolio Strategies's FULC Position: Q2 2026 in Review
Susquehanna Portfolio Strategies increased its Fulcrum Therapeutics (FULC) stake by 343% in Q2 2026, buying an estimated $403K and bringing the position to 85,580 shares worth $313K. The position accounts for 0.01% of the portfolio, ranked #740.
Susquehanna Portfolio Strategies first reported a position in FULC in Q4 2023 and has held it in 5 quarters since. The position peaked at $1.59M in Q1 2024. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.
- Susquehanna Portfolio Strategies held 85,580 shares of Fulcrum Therapeutics worth $313K as of Q2 2026.
- Susquehanna Portfolio Strategies bought 66,259 Fulcrum Therapeutics shares in Q2 2026, an estimated $403K.
- Fulcrum Therapeutics made up 0.01% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #740 holding.
- Susquehanna Portfolio Strategies first reported a position in Fulcrum Therapeutics in Q4 2023 and has held it in 5 quarters since.
- Susquehanna Portfolio Strategies's Fulcrum Therapeutics position peaked at $1.59M in Q1 2024.
- 154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.
Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.